Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) reported 2025 financial results, with revenue rising 5.5% YoY to HKD 12.28 billion (USD 1.084 billion) – 14.8% growth excluding VBP impact. The company achieved a transformation milestone as innovative barrier products reached ~50% of revenue (vs. 40% prior year). The radiopharmaceutical oncology segment surged 61.0% to HKD 950 million (RMB 839 million) – a 15-fold increase over four years – anchored by YiGanTai (SIR-Spheres Y-90), now the world’s only FDA-approved dual-indication selective internal radiation therapy for hepatocellular carcinoma (HCC) and colorectal cancer liver metastases.
FDA dual indication for YiGanTai validates world-class development; supports ex-China expansion
Pipeline Depth
4 radiopharmaceutical assets in development – sustainable growth engine beyond YiGanTai maturation
Revenue Mix Target
50% innovative products achieved; 60%+ target by 2027 via radiopharma and biologics expansion
Commercial Timeline: TLX591-CDx China approval 2026; GPN01530 U.S. Phase I/II data 2027; GPN02006 global Phase III 2028
Market Positioning:Only China pharma with FDA-approved radiopharmaceutical; theranostics leader vs. Novartis (Pluvicto) and Bayer (Xofigo)
Forward‑Looking Statements This brief contains forward‑looking statements regarding radiopharmaceutical pipeline progression, NDA approvals, and innovation revenue mix expansion. Actual results may differ due to regulatory review timelines, competitive dynamics in radioligand therapy, and manufacturing scale-up for radioactive isotopes.-Fineline Info & Tech
By Fineline Cube 